

# ecancer

the leading oncology channel



Journal



Video



News



Education



## ecancer.org

**ecancer.org** is a free online platform for oncology professionals incorporating an open-access journal, news, video and education.



1 Who we are	2 Statistics since launch	3 Editorial Board	4 Journal News and Scope	5 - 6 Abstracts
7 - 8 ecancer.tv	9 Education	10 Latin American Edition	12 ecancerpatient	13 Supporters

## Statistics since launch in 2007



2.5 million visitors  
from 196 countries



filmed at 142  
international conferences



videos viewed 10  
million times

Other Medical  
Professionals

Nurses

Radiation Oncologists

Surgeons

Industry

Research Scientists

Medical Oncologists



11,000 members

Journal



Video



News



Education



Twitter



6,200

Facebook



1200

LinkedIn



1700

iTunes U



19,000



## Editorial Board

Professor Claudio Basilico  
NYU School of Medicine, New York, USA

Professor Peter Boyle  
International Prevention Research Institute, Lyon, France

Professor Pier Paolo Di Fiore  
European Institute of Oncology, Milan, Italy

Professor Alexander Eggermont  
Institut Gustave Roussy, Paris, France

Professor Aaron Goldhirsch  
European Institute of Oncology, Milan, Italy

Professor Gordon McVie, Managing Editor  
European Institute of Oncology, Milan, Italy

Professor Roberto Orecchia  
University of Milan and European Institute of Oncology, Milan, Italy

Professor Pier Giuseppe Pelicci  
European Institute of Oncology, Milan, Italy

Professor Umberto Veronesi, Founding Editor  
European Institute of Oncology, Milan, Italy

Professor Giuseppe Viale  
University of Milan and European Institute of Oncology, Milan, Italy

Professor Luis Pinillos-Ashton  
National Cancer Institute of Peru (INEN), Lima, Peru

Maria S Pombo-de-Oliveira  
Research Center of Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil

Professor Rajiv Sarin  
Advanced Centre for Treatment Research and Education in Cancer (ACTREC), Tata Memorial Centre, Mumbai, India

Professor Cornelis J H van de Velde  
Leiden University Medical Center, The Netherlands

ecancermedicalsecience

ecancermedicalsecience is the open access cancer journal of the European Institute of Oncology, Milan (IEO) and the Organisation of European Cancer Institutes (OEI).

### Journal facts and figures


- No article processing charge for those without funding
- No subscription charges
- Publication in two months
- Rejection rate 60%
- Submissions accepted in English, Spanish and Portuguese
- Articles viewed 23,000 times a month

Indexed in PubMed, PubMed Central, Scopus, Embase, EBSCO and Google Scholar

The **Founding Editors** are highly respected and authoritative leaders each representing a different field of cancer research.



**Professor Gordon McVie** is the Managing Editor of ecancermedicalsecience. He is widely regarded as a leading international authority in the research and treatment of cancer and is responsible for Clinical Research Coordination, Strategy and International Affairs at the European Institute of Oncology.



**Professor Umberto Veronesi** is the Founding Editor of ecancermedicalsecience. He is the Founder and Emeritus Director of the European Institute of Oncology, Milan and is the pioneer of breast-conserving surgery.

### New Article Level Metrics

We're pleased to announce that **ecancermedicalsecience** has now introduced Article Level Metrics. This new functionality gives authors and readers the ability to discover the wider impact of individual articles in a way that was not previously possible. Authors will now be able to track their article across the internet and access statistics on how many people have read their work in a variety of international repositories, social media and online reference managers.

Currently, the metrics included are: views of each article on **ecancer**, views of the full text on PubMed Central, shares on Mendeley, citations in PubMed Central and Twitter mentions. We plan to develop a wider range of metrics as more become available.



### Journal scope

We consider articles on all aspects of research relating to cancer, including molecular biology, genetics, pathophysiology, epidemiology, clinical reports, controlled trials and cancer policy. **ecancermedicalsecience** accepts the results of negative clinical trials and outlier data.



Views of ecancermedicalsecience articles on PubMed Central

"As an organisation that both funds and conducts research it is vitally important that we know the impact that our research is having. With the article level metrics feature on the ecancer website it is easy for us to track just how many people are accessing our publications so that we know our work is having a continuing benefit long after the research has been published."

Dr Ian Lewis, Director of Research and Policy,  
Tenovus Cancer Care, Wales, UK

### Special issues

We publish a minimum of four special issues a year on hot topics in a wide range of subject areas. New special issues published recently include **Prostate cancer in black men**, **Palliative care in Sub-Saharan Africa** and **Fertility sparing treatment in gynaecological cancers**. Upcoming topics to be covered are: **Cancer and metabolism**, **Cervical cancer prevention** and **Gastrological cancers in Latin America**. Check out [ecancer.org/special-issues](http://ecancer.org/special-issues) to view them all.

If you have any suggestions for potential special issues, or are interested in becoming a guest editor or author, please contact our scientific editor, Dr Linda Cairns at [editor@ecancer.org](mailto:editor@ecancer.org)



over **2000** authors have published for free



**461** articles from **53** countries

# Abstracts

The following is a small selection of **ecancermedalscience** abstracts, all of these articles appear in PubMed Central and are freely available to view online.

## Clinical Study

### Repurposing drugs in oncology (ReDO)-cimetidine as an anti-cancer agent

**Pan Pantziarka<sup>1,2</sup>, Gauthier Bouche<sup>1</sup>, Lydie Meheus<sup>1</sup>, Vidula Sukhatme<sup>3</sup> and Vikas P Sukhatme<sup>3,4</sup>**

<sup>1</sup>Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium

<sup>2</sup>The George Pantziarka TP53 Trust, London KT1 2JP, UK

<sup>3</sup>GlobalCures, Inc; Newton MA 02459, USA

<sup>4</sup>Beth Israel Deaconess Medical Centre and Harvard Medical School, Boston, MA 02215, USA

Correspondence to: **Pan Pantziarka**  
Email: [pan.pantziarka@anticancerfund.org](mailto:pan.pantziarka@anticancerfund.org)

<http://ecancer.org/journal/8/485>

Cimetidine, the first H2 receptor antagonist in widespread clinical use, has anti-cancer properties that have been elucidated in a broad range of pre-clinical and clinical studies for a number of different cancer types. These data are summarised and discussed in relation to a number of distinct mechanisms of action. Based on the evidence presented, it is proposed that cimetidine would synergise with a range of other drugs, including existing chemotherapeutics, and that further exploration of the potential of cimetidine as an anti-cancer therapeutic is warranted. Furthermore, there is compelling evidence that cimetidine administration during the peri-operative period may provide a survival benefit in some cancers. A number of possible combinations with other drugs are discussed in the supplementary material accompanying this paper.

"The reasons for choosing to submit to **ecancermedalscience** were the facts that it is PubMed indexed, open access (which is really a plus regarding dissemination in the scientific community and citations) and the innovative platform which gives it a lot of visibility, with videos and a large presence at major conferences."

Ana Catarina Pinto, Jules Bordet Institute, Belgium

## Policy

### PACE Continuous Innovation Indicators—a novel tool to measure progress in cancer treatments

**Silvia Paddock<sup>1</sup>, Lauren Brum<sup>1</sup>, Kathleen Sorrow<sup>1</sup>, Samuel Thomas<sup>1</sup>, Susan Spence<sup>1</sup>, Catharina Maulbecker-Armstrong<sup>2</sup>, Clifford Goodman<sup>3</sup>, Michael Peake<sup>4</sup>, Gordon McVie<sup>5</sup>, Gary Geipel<sup>6</sup> and Rose Li<sup>1</sup>**

<sup>1</sup>Rose Li and Associates, Inc., Bethesda, Maryland 20817, USA

<sup>2</sup>Prevention and Health Promotion, State of Hessen, 65187 Wiesbaden, Germany

<sup>3</sup>Center for Comparative Effectiveness Research, The Lewin Group, Falls Church, Virginia 22042, USA

<sup>4</sup>University of Leicester, LE1 7RH, United Kingdom; National Lung Cancer Audit, Clinical Effectiveness and Evaluation Unit, Royal College of Physicians, London NW1 4LE, United Kingdom; National Cancer Intelligence Network, London SE1 8UG, United Kingdom

<sup>5</sup>European Institute of Oncology, Milan 20146, Italy; University of Milan, Italy; University of Glasgow, G12 8QQ, United Kingdom; University of Wales, Cardiff, South Glam CF10 3NS, United Kingdom; Founding Editor of **ecancer.org**

<sup>6</sup>Lilly Oncology, Indianapolis, Indiana 46285, USA  
Correspondence to: **Silvia Paddock**  
Email: [silvia.paddock@roseliassociates.com](mailto:silvia.paddock@roseliassociates.com)

<http://ecancer.org/journal/9/498>

Concerns about rising health care costs and the often incremental nature of improvements in health outcomes continue to fuel intense debates about 'progress' and 'value' in cancer research. In times of tightening fiscal constraints, it is increasingly important for patients and their representatives to define what constitutes 'value' to them. It is clear that diverse stakeholders have different priorities. Harmonisation of values may be neither possible nor desirable. Stakeholders lack tools to visualise or otherwise express these differences and to track progress in cancer treatments based on variable sets of values.

The Patient Access to Cancer care Excellence (PACE) Continuous Innovation Indicators are novel, scientifically rigorous progress trackers that employ a three-step process to quantify progress in cancer treatments: 1) mine the literature to determine the strength of the evidence supporting each treatment; 2) allow users to weight the analysis according to their priorities and values; and 3) calculate Evidence Scores (E-Scores), a novel measure to track progress, based on the strength of the evidence weighted by the assigned value.

We herein introduce a novel, flexible value model, show how the values from the model can be used to weight the evidence from the scientific literature to obtain E-Scores, and illustrate how assigning different values to new treatments influences the E-Scores.

"**ecancermedalscience** is an innovative journal in the field of cancer. The exciting features of **ecancer** are: the articles are published within the scheduled time, the worldwide free access, user friendly submission system, and dedicated editorial team."

Dr.Praveen Rathod, Asst. Professor in Gynaecologic Oncology, Kidwai Memorial Institute of Oncology (KMIO), India

## Special Issue

### The current situation in education and training of health-care professionals across Africa to optimise the delivery of palliative care for cancer patients

**FM Rawlinson<sup>1</sup>, L Gwyther<sup>2</sup>, F Kiyange<sup>3</sup>, E Luyirika<sup>3</sup>, M Meiring<sup>4</sup> and J Downing<sup>5</sup>**

<sup>1</sup>Department of Palliative Medicine, Cardiff University, Velindre Hospital, Cardiff CF14 2TL, Wales, UK

<sup>2</sup>Hospice Palliative Care Association of South Africa and Senior Lecturer, palliative medicine, University of Cape Town Anzio Road, Observatory, Cape Town, South Africa

<sup>3</sup>African Palliative Care Association, PO Box 72518, Plot 95, Dr Gibbons Road, Makindye, Kampala, Uganda

<sup>4</sup>Sarah Fox Convalescent Hospital and PATCH-SA (SA Children's Palliative Care Network), Lecturer, palliative medicine, University of Cape Town Anzio Road, Observatory, Cape Town, South Africa

<sup>5</sup>Honorary Professor, Makerere University, PO Box 7062, Kampala, Uganda; International Palliative Care Consultant

Correspondence to: **Fiona Rawlinson**  
Email: [Fiona.Rawlinson@wales.nhs.uk](mailto:Fiona.Rawlinson@wales.nhs.uk)

<http://ecancer.org/journal/8/492>

The need for palliative care education remains vital to contribute to the quality of life of patients, both adults and children, with cancer in Africa. The number of patients with cancer continues to rise, and with them the burden of palliative care needs. Palliative care has been present in Africa for nearly four decades, and a number of services are developing in response to the HIV/AIDS epidemic. However, the needs of cancer patients remain a challenge. Education and training initiatives have developed throughout this time, using a combination of educational methods, including, more recently, e-learning initiatives.

The role of international and national organisations in supporting education has been pivotal in developing models of education and training that are robust, sustainable, and affordable. Developing a material for education and professional development needs to continue in close collaboration with that already in production in order to optimise available resources. Seeking ways to evaluate programmes in terms of their impact on patient care remains an important part of programme delivery. This article reviews the current situation.

## Conference Report

### From precision medicine to cancer care through the immunome: highlights from the European Society of Medical Oncology Congress, Madrid, 26–30th September 2014

**Giuseppe Curigliano**

Division of Experimental Therapy, European Institute of Oncology, Via Ripamonti 435, Milan 20141, Italy

Correspondence to: **Giuseppe Curigliano**  
Email: [giuseppe.curigliano@ieo.it](mailto:giuseppe.curigliano@ieo.it)

<http://ecancer.org/journal/8/472>

The recognition that cancer is a 'spectrum' of diseases, and that medical oncologists should achieve 'convergence' from 'divergence' to treat cancer patients was the main theme of the 2014 European Society of Medical Oncology (ESMO) Congress. The meeting assembled 19,859 participants from nearly 134 countries worldwide. The educational content was centered on precision medicine in cancer care, from mutational burden to the immunome, through the epigenome and the proteome. Precision medicine has been defined as the tailoring of medical treatment to the characteristics of an individual patient. Knowing an individual's genomics has created a remarkable and unprecedented opportunity to improve medical treatment and develop preventative strategies to preserve health. Clinical oncologists across the range of diseases recognise that for precision medicine to take hold, it will require intensive, rigorous validation that these new approaches do indeed improve patient outcomes. Not all molecular alterations are predictive of response to a specific targeted treatment nor are they all druggable, raising issues of cost-benefit, validation of specific biomarkers, and of managing patient expectations. Addressing all these issues will be essential for the medical community to embrace any given opportunities. Along with it, it will also require educational programmes that squarely address the knowledge chasm that currently exists for practicing physicians. The promise of genomic and precision medicine has created greater demands for both those providing the scientific expertise—bioinformatics, statisticians, molecular biologists—and those delivering clinical care—physicians, nurses, psychologists—to the patients. This ESMO 2014 report will highlight the major findings of this outstanding meeting.

PMC







### ePOSSOM: New free online education for postgraduate surgeons

Richard Bamford, General Surgery registrar at Severn Deanery Postgraduate School of Surgery talks to ecancer about the new elearning resources for postgraduate surgeons. The collaborative effort from ecancer and Health Education South West brought ePOSSOM (ecancer POSTgraduate school of Surgery Surgical Oncology Modules) to life.

Richard Bamford and head author, Katrina Butcher also from Severn Deanery have worked together to create a great article on Innovation in elearning: learning for all.

The free online course on pancreatic cancer surgery is available from ecancer's education section - a great resource for postgraduate surgical trainees looking to expand or refresh their knowledge on pancreatic cancer surgery.

**Richard Bamford - Severn Postgraduate School of Surgery, Bristol, UK**  
<http://ecancer.org/video/3165>

**87% of doctors** who watch ecancer videos have said that they will change their current practice based on the information they have learnt.

"I would like to take this opportunity to congratulate you on the extremely important job you are doing, delivering the message of oncology to both the medical community and the public."

Professor Vesna Kesik, President, ESGO



### ASH 2014: Expert discussion on the latest in CLL

Prof Gribben (Queen Mary University London, London, UK) and Prof Stilgenbauer (Universitätsklinikum Ulm, Ulm, Germany) review the data and opinions arising from ASH 2014 about the treatment of chronic lymphocytic leukaemia (CLL) for ecancertv.

The experts offer a comprehensive analysis of the current treatments of the disease, noting the importance of cytogenetics and the unique genetic characteristics of individual patients. They also touch on some of the key highlights presented at ASH 2014.

**Prof John Gribben and Prof Stephan Stilgenbauer**  
<http://ecancer.org/video/3327>



### Adding ultrasound to routine mammography improves cancer detection in dense breasts

Dr Weigert talks to ecancertv at SABCS 2014 about her research which found that the number of breast cancers detected in women with dense breasts was increased when those women who had a normal mammogram underwent an additional breast ultrasound screening.

**Dr Jean Weigert - Cancer Center of Central Connecticut, New Britain, USA**  
<http://ecancer.org/video/3388>

Please contact Jon Birch [jon@ecancer.org](mailto:jon@ecancer.org) if you are interested in being interviewed by ecancer.tv.

"I was very pleased with how my interview turned out. I greatly appreciate the opportunity to bring international attention to our growing field of cancer survivorship research and care."

Dr Julia Rowland, National Cancer Institute, USA



### Treatment options in castration-resistant prostate cancer: Expert discussion

Prof Karim Fizazi chairs a discussion with Prof Eleni Efstathiou, Dr Bertrand Tombal and Prof Stephane Oudard about the latest in prostate cancer treatment for ecancertv at ESMO 2014.

They discuss the treatment paradigms, novel drugs and new, verified treatment regimens and advances announced at the ESMO Congress.

Specifically, they look at what's new in castration-resistant prostate cancer, clarify the use of combination and sequential therapies, and debate the hot topics coming out of ESMO 2014.

**Prof Karim Fizazi, Prof Eleni Efstathiou, Dr Bertrand Tombal and Prof Stephane Oudard**  
<http://ecancer.org/video/3104>



### New emerging treatments and challenges in MCL, MM and CLL: Expert panel discussion

Prof Rule (Derriford Hospital, Plymouth, UK) chairs a discussion with Dr Mateos (University Hospital of Salamanca, Salamanca, Spain), Prof Ghia (Università Vita-Salute San Raffaele, Milan, Italy), and Prof Palumbo (University of Turin, Turin, Italy) for ecancertv at the Hematology Debate in Berlin about new emerging treatments and challenges in mantle cell lymphoma (MCL), multiple myeloma (MM) and chronic lymphocytic leukaemia (CLL).

**Prof Simon Rule, Dr Maria-Victoria Mateos, Prof Paolo Ghia, Prof Antonio Palumbo**  
<http://ecancer.org/video/3290>



### Prof Laskey receives Lifetime Achievement Prize

Prof Laskey talks to ecancertv at NCRI 2014 about the Lifetime Achievement Prize he received from Cancer Research UK, and gives us an insight into some of the valuable research he's done to earn it.

**Prof Ronald Laskey CBE - University of Cambridge, Cambridge, UK**  
<http://ecancer.org/video/3255>

3,500

Expert Interviews

10M

Video Views


7000

News Stories

World's largest collection of oncology videos

## An innovative approach to elearning development

The ePOSSOM (ecancer POst Graduate School of Surgery Surgical Oncology Modules) project has launched a series of educational modules to meet the needs of post-graduate surgical trainees looking to extend their knowledge on pancreatic cancer.



The ePOSSOM collaboration was jointly developed by ecancer and the Severn Postgraduate School of Surgery, where surgical trainees led by Miss Katrina Butcher developed the content of the modules, providing key educational information for other surgical trainees and healthcare professionals.

*"ePOSSOM creates innovative e-learning material for audiences across the world, allowing each learner access to complex evidence-based medicine, wherever their learning environment allows them,"*

Miss Butcher writes in the accompanying editorial.

These modules follow the UK ISCP (Intercollegiate Surgical Curriculum Programme) Curriculum, and aim to be a concise, up-to-date best evidence resource, for either new learning or revision. Experts from across the UK have contributed to and peer-reviewed the modules to ensure that the content is of the highest scientific quality – and poised on the frontier of pancreatic cancer knowledge.

In this unique and flexible educational experience, the learner is guided through the modules with a variety of learning techniques, including surgical videos, case examples, quizzes and games.

*"These modules provide a unique learning experience in a subject not tackled before in this way,"* says Miss Butcher.

The modules are available for free here: <http://ecancer.org/education/course/7-pancreatic-cancer-surgery-course-for-post-graduate-surgical-trainees.php>

Editorial by Miss Butcher:  
<http://10.0.13.4/ecancer.2014.ed45>

Other elearning courses provided for free include:

- Management of prostate cancer in older patients
- The TNM Classification System
- Personalised medicine
- Palliative care for healthcare professionals in Africa
- Tobacco cessation for nurses in Eastern Europe

## Latin American edition

Cancer is the second leading cause of death in the Americas and accounts for an increasing percent of the disease burden in Latin America and the Caribbean (LAC). By 2030, **1.7 million** cases of cancer will be diagnosed in the region, and more than a million people will die from cancer each year.

In recognition of the wealth of research coming out of Spanish speaking countries **ecancermedalscience** accepts submissions in Spanish. Articles are reviewed in Spanish, and then, once accepted, translated into English (FREE of charge), to be published in **ecancermedalscience**.

Supported by The Swiss Bridge Foundation

SWISS BRIDGE  
INVEST IN CANCER RESEARCH WORLDWIDE

Following the success of our Spanish site, and in acknowledgment of the rapidly increasing amount of high quality research being produced by Brazil, we are now offering the same service for Portuguese speaking authors.



"Latin America and the Caribbean have around 600 million inhabitants and approximately

1 million new cases of cancer per year according to GLOBOCAN 2012. Mortality-to-incidence cancer ratio are high compared to developed countries, tumour types such as cervical carcinoma are still extremely prevalent and inequalities in screening, diagnosis and access to optimal treatment exist in this region. Scientific data are scarce in this area, therefore ecancermedalscience provides the opportunity for investigators to generate regional information on epidemiological studies, clinical and translational research. High-quality peer-reviewed information is key in understanding the reality and pitfalls of cancer care in Latin America."

Gustavo Werutsky, Scientific Director, Latin American Cooperative Oncology Group (LACOG)




ecancer hosted the 1st International ecancer Symposium on breast cancer on **5 -7 March 2015 in Lima, Peru**. The event brought together top European and Latin American experts to

discuss the latest treatment advances and attitudes towards breast cancer.

This is the first of many exciting initiatives which will have a positive impact on cancer care in Latin America.

[www.ecancersimposioperu.com](http://www.ecancersimposioperu.com)



91 hours of  
elearning modules



in partnership with 103  
experts from 23 countries





Prof. Umberto Veronesi - Oncologist  
Valentina Gambino - She graduated in Biological Sciences

## BECAUSE SCIENTIFIC RESEARCH IS GOOD FOR EVERYONE. FOR YOU TOO.

OUR COMMITMENT TODAY. The Umberto Veronesi Foundation was founded in 2003, intending to foster **scientific research** by allocating research grants to doctors and researchers and through supporting cutting edge research projects.

At the same time, the Foundation is active in the **public understanding and importance of science**, in order to make the results and discoveries of science a collective heritage.



The ideal and concrete support of everyone is important. Each contribution will allow us to continue the initiatives already in progress and to identify new areas of intervention.



[www.oeci.eu](http://www.oeci.eu)  
For membership contact:  
[oeci@oeci.eu](mailto:oeci@oeci.eu)

DEVELOPING  
THE FUTURE IN  
COMPREHENSIVE  
CANCER CARE



- ★ OECI Members that received the OECI accreditation
- ★ OECI Members into the accreditation process
- Other OECI Members


ACCREDITATION  
AND  
DESIGNATION

The OECI is a non-governmental Organisation founded in Vienna, in 1979.

The primary objectives of its 70 Members are to reduce fragmentation and to give all European cancer patients the possibility of receiving the best available care. The OECI Members have established themselves in the innovation frontline by tailoring solutions to the individual patient, by gaining in efficiency and efficacy and with the potential to transform the way healthcare is delivered today.

To better achieve its goals, the Organisation works in close collaboration with the European Cancer Patients Coalition.

The OECI goals are achieved by promoting and strengthening the concept of Comprehensive Cancer Centres in Europe in order to improve quality in cancer care and translational research, as well as from an organisational viewpoint. In an effort to efficiently contribute towards an increase in the quality of care, 45% of all OECI Members are already participating in the OECI Accreditation/Designation programme.



ecancerpatient



**ecancerpatient.org** is our empowerment platform that aims to help patients have a greater influence in their care. By increasing understanding of the latest treatments, the aim is for more patients to receive the most appropriate care for them as an individual.

Over the past two years, ecancerpatient has created over **45** patient friendly videos which have been watched over **85,000** times.

ecancerpatient provides information for patients to use while discussing treatment options with their doctor. Our videos are of cancer specialists talking

about the most recent advances in care and are designed to empower patients to become more involved in vital treatment decisions.

To ensure the information within the videos is accessible for patients, ecancer teamed up with patient groups to develop our patient friendly format. The subjects of the videos are leading cancer specialists; therefore an additional level of information is needed to make information digestible for patients. To do this we ensure the videos are broken down into short, palatable sections and have additional explanations where medical terms are used.


A summary of the information is then provided for patients to print off and use as a reminder when they are discussing this information with their doctor.

To view the videos or find out more please visit **[www.ecancerpatient.org](http://www.ecancerpatient.org)**


Clear key messages



Cancer specialist



Explanation of key terms



ecancer.org

### The Bridge between the Swiss Private Banking Community and international cancer research

- ... financially supports cancer research worldwide
- ... generates up to 2 million Swiss francs in donations every year
- ... the SWISS BRIDGE AWARD for international researchers
- ... no expenses deducted from donations for research
- ... world-class scientific standing
- ... one of the major funders of *ecancer*

Thank you to all our supporters, including our founding charities, the European Cancer Organisation (ECCO), Fondazione Umberto Veronesi, the European Institute of Oncology (IEO) and Swiss Bridge.




*ecancer* is not-for-profit and is supported by charity, sponsorship and grants to remain editorially independent.

Published by Cancer Intelligence Ltd, 2nd Floor, 154 Cheltenham Road, Bristol, BS6 5RL, UK.



## Want your meeting to reach thousands more oncologists?

Broadcast your satellite through *ecancer*



- Expand the impact of your scientific meeting
- Disseminate to over 0.5 M yearly visitors
- On demand access 24/7
- Geo targeting and password protection available

[www.ecancer.org/education](http://www.ecancer.org/education)



Free

**ecancer**

the leading oncology channel

Now available on  
**iPad and Android**



Available on the  
**App Store**



ANDROID APP ON  
**Google play**

12:20 PM

**ecancertv**

Prostate Cancer Debate 2013; Evolving treatment options in castration-resistant prostate cancer

Advances in treatments for haematologic malignancies from the Sarah Cannon Research Institute presented at ASH 2012

Multiple myeloma advances for the future suggested by phase I clinical research

Clofarabine and other novel agents in AML; Interview with Alan Burnett at ASH 2012



**VIDEOS**



**EVENTS**



**SHARE**

Journal  
**Videos**  
**News**

